<div id="readability-page-1"><p>Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) insider Andrew Hollman Meyer sold 1,879 shares of the company's stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $25,798.67. Following the completion of the transaction, the insider owned 83,095 shares in the company, valued at approximately $1,140,894.35. This trade represents a 2.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.</p><div><p><span></span><span>Get <strong>Janux Therapeutics</strong> alerts:</span></p></div><p>Andrew Hollman Meyer also recently made the following trade(s): </p><ul><li>On Monday, December 1st, Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock. The stock was sold at an average price of $32.98, for a total value of $109,922.34. </li><li>On Friday, November 14th, Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $99,990.00. </li><li>On Tuesday, October 28th, Andrew Hollman Meyer sold 16,665 shares of Janux Therapeutics stock. The stock was sold at an average price of $30.06, for a total value of $500,949.90. </li></ul><h2>Janux Therapeutics Stock Down 1.1%</h2><p>Shares of JANX traded down $0.15 during midday trading on Friday, reaching $13.65. 1,533,974 shares of the stock were exchanged, compared to its average volume of 2,182,684. Janux Therapeutics, Inc. has a twelve month low of $13.52 and a twelve month high of $61.59. The company has a market cap of $821.05 million, a P/E ratio of -8.13 and a beta of 2.88. The stock's 50 day simple moving average is $22.51 and its 200 day simple moving average is $23.74. </p><p>Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.21. The business had revenue of $10.00 million during the quarter, compared to analyst estimates of $3.07 million.  As a group, analysts predict that  Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year. </p><h2>Janux Therapeutics News Summary</h2><p>Here are the key news stories impacting Janux Therapeutics this week:</p><ul>   <li><span>Negative Sentiment: </span>CEO David Alan Campbell sold 8,072 shares (~$110,829); he still holds 284,982 shares. <i></i><span>Form 4 - Campbell</span></li>   <li><span>Negative Sentiment: </span>Insider Thomas Diraimondo sold 2,505 shares (~$34,394); remaining position ~124,425 shares. <i></i><span>Form 4 - Diraimondo</span></li>   <li><span>Negative Sentiment: </span>Zachariah McIver sold 2,714 shares (~$37,263); post-sale holding ~23,286 shares. <i></i><span>Form 4 - McIver</span></li>   <li><span>Negative Sentiment: </span>VP Maria Dobek sold 1,462 shares (~$20,073); holds ~15,373 shares after the sale. <i></i><span>Form 4 - Dobek</span></li>   <li><span>Negative Sentiment: </span>Insider Charles M. Winter sold 2,401 shares (~$32,966); remaining holding ~77,721 shares. <i></i><span>Form 4 - Winter</span></li> </ul><h2>Hedge Funds Weigh In On Janux Therapeutics</h2><p>A number of institutional investors and hedge funds have recently bought and sold shares of JANX. Osaic Holdings Inc. raised its holdings in  Janux Therapeutics by 704.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company's stock worth $80,000 after purchasing an additional 3,037 shares during the last quarter.  Virtus Investment Advisers LLC raised its stake in  Janux Therapeutics by 37.9% during the second quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company's stock worth $85,000 after buying an additional 1,011 shares during the last quarter.  Tower Research Capital LLC TRC lifted its holdings in  Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company's stock valued at $91,000 after buying an additional 2,502 shares during the period.  Ameritas Investment Partners Inc. lifted its holdings in  Janux Therapeutics by 25.6% in the second quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company's stock valued at $93,000 after buying an additional 820 shares during the period.  Finally, Winthrop Capital Management LLC bought a new stake in  Janux Therapeutics during the third quarter valued at $106,000. Institutional investors and hedge funds own  75.39% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several equities research analysts recently weighed in on JANX shares. HC Wainwright cut their price objective on shares of Janux Therapeutics from $70.00 to $45.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday, December 2nd. Stifel Nicolaus cut their price target on shares of Janux Therapeutics from $46.00 to $38.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday, December 2nd. Cantor Fitzgerald reduced their price target on shares of Janux Therapeutics from $200.00 to $150.00 and set an &#34;overweight&#34; rating on the stock in a research report on Tuesday, December 2nd. UBS Group  restated a &#34;buy&#34; rating and set a $57.00 price objective on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Finally, Bank of America cut their target price on Janux Therapeutics from $58.00 to $49.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday, December 2nd. Twelve equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one  has issued  a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $61.08.</p><p><b>View Our Latest Research Report on Janux Therapeutics</b></p><h2>Janux Therapeutics Company Profile</h2> (Get Free Report)<p>Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX. </p><p>Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Janux Therapeutics</li><li>Trump just signed it</li><li>Protect Your Bank Account with THESE 4 Simple Steps</li><li>The Crash Has Already Started (Most Just Don’t See It Yet)</li><li>A month before the crash</li><li>But this $2 Gold Stock Before May 20, 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFOWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Janux Therapeutics Right Now?</h2><p>Before you consider Janux Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.</p><p>While Janux Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

JANX

<p>Andrew Hollman Meyer, an insider at Janux Therapeutics (NASDAQ:JANX), sold 1,879 shares at an average price of $13.73, totaling $25,798.67. Post-sale, he holds 83,095 shares valued at approximately $1,140,894.35, marking a 2.21% decrease in his position. The stock has seen a decline of 1.1%, trading at $13.65. Recent insider sales include CEO David Alan Campbell and others, reflecting negative sentiment. Institutional investors own 75.39% of the company, with recent upgrades and downgrades from analysts affecting stock ratings.</p>

Andrew Hollman Meyer Sells 1,879 Shares of Janux Therapeutics (NASDAQ:JANX) Stock